Abstract: Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic options. We performed a systematic review and a meta-analysis of randomized-controlled trials (RCTs) of first-line anti-PD-1/PD-L1 agents vs. sunitinib, presenting efficacy data in the sub-group of sRCC patients. The systematic research was conducted on Google Scholar, Cochrane Library, PubMed and Embase and updated until 31th January, 2020. Abstracts from ESMO and ASCO (2010–2019) were also reviewed. Full texts and abstracts reporting about RCTs testing first-line anti-PD-1/PD-L1 agents vs. sunitinib in RCC were included if sRCC sub-group analyses of either PFS (progression-free survival), OS (overall survival) or radiological response rate were available. Pooled data from 3814 RCC patients in the ITT (intention-to-treat) population and from 512 sRCC patients were included in the quantitative synthesis. In the sRCC sub-group vs. the ITT population, pooled estimates of the PFS-HRs were 0.57 (95%: 0.45–0.74) vs. 0.79 (95% CI: 0.70–0.89), respectively, with a statistically meaningful interaction favoring the sRCC sub-group (pooled ratio of the PFS-HRs = 0.64; 95% CI: 0.50–0.82; p < 0.001). Pooled estimates of the difference in CR-R (complete response-rate) achieved with anti-PD-1/PDL-1 agents vs. sunitinib were + 0.10 (95% CI: 0.04–0.16) vs. + 0.04 (95% CI: 0.00–0.07) in the sRCC vs. the non-sRCC sub groups, with a statistically meaningful difference of + 0.06 (95% CI: 0.02–0.10; p = 0.007) favoring the sRCC sub-group. Sarcomatoid histology may be associated with improved efficacy of anti PD-1/PDL-1 agents vs. sunitinib in terms of PFS and CR-R.
Keywords: renal cell carcinoma; sarcomatoid; immune checkpoint inhibitors; PD-1; PD-L1

1. Introduction

Renal cell carcinoma (RCC) represents the ninth and 14th most commonly diagnosed cancers in men and women, respectively, with an estimated >400,000 new RCC cases reported in 2018 [1] and a cumulative life-time mortality risk varying in range of 0.1–0.7% worldwide [2]. Western Europe and North America present the highest age-standardized incidence rates [2]. Metastatic RCC is virtually incurable, although median survival among risk groups has approximately doubled with the advent of targeted therapy [3]. The use of anti PD-1 (programmed death 1)/PD-L1 (programmed death - ligand 1) agents in combination with anti-VEGF (vascular endothelial growth factor) or anti CTLA-4(Cytotoxic T-Lymphocyte Antigen 4) agents [4,5] has led to further improvements in the life expectancy of patients with metastatic RCC. Importantly, while anti-VEGF therapy is effective regardless of the prognostic risk-group, ipilimumab+nivolumab vs. sunitinib was effective in intermediate- and poor-risk patients but not in patients at good prognosis, which has made it finally compulsory for risk class to be incorporated in the therapeutic algorithm.

Adverse histologic features, including necrosis, lymphovascular invasion, high nuclear grade, rhabdoid as well as sarcomatoid histology have a remarkable prognostic value, even in patients with small renal masses [6]. Sarcomatoid histology, which is characterized by the loss of typical epithelial features (“dedifferentiation”), is reported in approximately 5–10% of cases, most frequently in clear-cell RCC [7]. In metastatic RCC patients, sarcomatoid histology was associated with a poor median disease-specific survival of 9 months [6], with chemotherapy and targeted therapy showing disappointing efficacy in these patients [8]. Anti PD-1/PDL-1 agents may be more effective in patients with sarcomatoid histology, possibly because of a higher PD-L1 expression [9] and a higher mutational burden [10].

This systematic review and meta-analysis aims to provide a pooled analysis of the available efficacy data of anti PD1/PDL-1-based therapy vs. sunitinib in patients with sarcomatoid RCC (sRCC) With the limitations imposed by data availability, exploratory analyses were performed to assess differences in efficacy of anti PD-1/PD-L1-based therapy vs. sunitinib between sarcomatoid and unselected/non-sarcomatoid RCC patients, as well as establishing the potentially optimal anti PD-1/PD-L1-based regimen against sRCC.

2. Methods

The search for relevant articles was performed by querying PubMed/MEDLINE, EMBASE, Google Scholar, Cochrane Library according to the PRISMA guidelines. The search terms included the following keywords: “sarcomatoid”, “renal cell carcinoma”, “kidney cancer”, “immunotherapy”, “PD-1”, “PD-L1”, “avelumab”, “atezolizumab”, “pembrolizumab”, “nivolumab”. Articles published since inception until January, 31st 2020 were evaluated for inclusion in the systematic review. Abstracts and presentations from ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) between 2010 and 2019 were also reviewed. Ten investigators (SL, IS, VA, CF, PM, RD, MR, RV, CF, DPP) worked in two separate groups that independently screened potentially relevant abstracts and retrieved the full texts of original data obtained with anti PD-1/PD-L1 agents in RCC.

Full papers and abstracts/presentations reporting original data obtained in RCC patients treated with anti PD-1/PD-L1 agents were assessed for inclusion in the systematic review. Articles reporting data about randomized-controlled clinical trials (RCTs) testing an anti PD-1/anti PD-L1 agent vs. sunitinib in patients with advanced RCC treated in the first-line setting were included in this meta-analysis if sub-group analysis of either PFS, OS or radiological response rate were available in sRCC patients, either in the same publication or in a separate article or abstract. Abstracts were only included
if providing original data useful for the purposes of this meta-analysis that were unavailable as a full paper.

Articles cited in the full papers assessed were also evaluated for inclusion in this meta-analysis. In case of duplicate publications, the most updated data were considered. Disagreements about studies were discussed among all investigators and resolved by CB. From each included study, the following data were extracted: name of study, first author and year of publication, study design and blinding, study phase, number of patients, median OS and PFS in the overall population and in the sarcomatoid sub-group, hazard ratio for PFS and/or OS in the overall population and in the sarcomatoid subgroup, partial and complete radiological response rates in the overall population and in the sarcomatoid subgroup. The quality of the included RCTs was assessed using the Jadad scale [11].

3. Data Analysis

The primary objective of the meta-analysis was to obtain pooled estimates of the partial response rates (PR-Rs), the complete response rates (CR-Rs), the hazard ratios for progression or death (PFS-HRs) and the hazard ratios for death (OS-HRs), reported in the sub-group of patients with sarcomatoid histology enrolled in RCTs of anti-PD-1 based therapy vs. sunitinib as first-line treatment of advanced RCC. The secondary objectives were to estimate differences in pooled PFS-HRs and OS-HRs between the sub-group of sRCC patients vs. the ITT population as well as to measure differences in the absolute improvements in PR-Rs and in the CR-Rs associated with use of anti-PD-1/PD-L1 based therapy vs. sunitinib (ΔPR-R and ΔCR-R) in the non-sRCC vs. in the sRCC sub-groups.

For PR-R and CR-R, data were presented as percentage and proportion difference with the 95% CIs, while for PFS-HR and OS-HR data were presented as HRs with the 95% CIs. We evaluated heterogeneity among studies using the $\chi^2$ Q test and $I^2$ statistics. For the Q test, significant heterogeneity was declared if $p < 0.05$, while $I^2$ values >50% were considered to indicate evident heterogeneity.

Publication bias was evaluated by visual asymmetry on funnel plots of PFS-HR against standard errors, in sarcomatoid sub-group and ITT population. Moreover, a regression test for funnel plot asymmetry was performed to verify whether the association between effect sizes and the related standard errors was statistically significant.

To explore differences in PFS-HR and OS-HR in patients with sarcomatoid histology vs. the ITT population as well as to compare proportion differences for PR-Rs and CR-Rs in patients with vs. patients without sarcomatoid histology, an interaction test was performed following the approach reported by Fisher et al. [12]. The pooled estimate of the HRs for progression or death (pooled PFS-HRs) and for death (pooled OS-HRs) in the sarcomatoid and in the ITT population and the pooled combination of the trial-specific interaction ratios of PFS- and OS-HR between the sarcomatoid vs. the ITT populations (pooled ratios of the PFS-HRs and OS-HRs) were obtained using random-effects models and reported with their corresponding 95% C.I. The pooled estimate of PR-Rs and CR-Rs with anti PD-1/PDL-1 agents vs. sunitinib (pooled PR-Rs and CR-Rs), as well as of the trial-specific interaction proportion differences in PR-Rs and CR-Rs with anti PD-1/PDL-1 agents vs. sunitinib between the sRCC vs. non sRCC sub-groups (pooled differences of ΔPR-R and ΔCR-R) were obtained using random-effects models and reported with their corresponding 95% C.I [12].

The results were also graphically displayed using forest plots where sRCC sub-group were compared to the entire ITT population (PFS- and OS-HR) or the non-sRCC subgroup (PR-Rs and CR-Rs). The pooled estimates were recalculated after excluding each single study according to a Leave-One-Out-analysis in order to evaluate the robustness of results and to show whether a single study influenced the overall estimate of the meta-analysis. The Leave-One-Out-analysis was applied for evaluation of the pooled ratio of the HRs for death and for progression/death and of the complete response and partial response rates.

Finally, a network meta-analysis was performed to compare the efficacy of each therapy with all the other therapies. However, due to the insufficient number of studies for each treatment (i.e., one trial for treatment, expect for one treatment, for which two studies were considered), we limited the...
analysis providing only a ranking of treatments from greatest to lowest efficacy, and results must be interpreted with caution. On the basis of a frequentist treatment ranking method, we computed the P-scores, which measure the extent of certainty that one treatment is better than another treatment, averaged over all competing treatments [13].

The statistical software R, version 3.6.0 (13) was used for all statistical analyses. Meta-analysis was performed using metafor package, version 2.1–0. The \( p \)-value < 0.05 was considered as statistically meaningful. Network meta-analysis was performed using the netmeta R package [14].

4. Results

4.1. Eligible Articles

Our database search retrieved 14087 abstracts. Of the 177 full-texts of clinical studies involving the use of anti PD-1/PD-L1 agent in RCC that were evaluated, 6 full text articles [15–20] reporting data from RCTs were finally included in the quantitative meta-analysis. Furthermore, four abstracts [21–24] reporting sub-group analysis in sRCC were also included in the quantitative meta-analysis. The flow chart of the systematic review is reported in Figure 1.

![Figure 1. Flow-diagram of the systematic review.](image)

Overall, the six full texts and four abstracts included reported original data from five different RCTs of anti PD-1/PDL-1 based therapy vs. sunitinib obtained in the ITT population and sRCC sub-group.
4.2. Quantitative Synthesis

Five different open-label RCTs of anti PD-1/PD-L1 therapy vs. sunitinib were included. Four RCTs were two-arm phase III trials [15–19], while one was a three-arm phase II trial [20]. All five RCTs included had a Jadad score of 3. Relevant findings of the trials included are reported in Table 1. Pooled data from a total of 3814 RCC patients in the ITT population and from a total of 512 patients in the sarcomatoid RCC sub-group were included in the quantitative synthesis.

Considering PFS-HR, the included studies did not show an evident reporting bias for both sarcomatoid sub-group and ITT population (Figure 2). Moreover, the regression test did not suggest a significant asymmetry in the respective funnel plots (p = 0.910 for sarcomatoid and p = 0.173 for ITT population).

![Figure 2. Interactions between HR for progression or death and sarcomatoid histology. Funnel plots of PFS-HR for sarcomatoid sub-group and ITT population. Publication bias was evaluated by visual asymmetry and p-values are obtained by regression tests for funnel plot asymmetry. The y-axis reports standard error while the x-axis reports the effect sizes, that is, HR for PFS in sarcomatoid sub-group (left-hand size) and ITT (right-hand side).]

Pooled estimates of PFS-HR were 0.79, 95% [0.70; 0.89] in the ITT population and 0.57, 95% [0.45; 0.74] in the sarcomatoid-only subgroup (Figure 3), while for OS-HR pooled estimates were 0.70, 95% [0.51; 1.10] in the ITT population and 0.56, 95% [0.40; 0.78] in the sarcomatoid-only subgroup (Figure 4). The pooled ratio of PFS-HRs and OS-HRs in the sarcomatoid vs. the ITT population were 0.64, 95% [0.50; 0.82] and 0.76, 95% [0.52; 1.10], respectively. Pooled interaction was statistically significant for PFS-HRs (p-value for interaction < 0.001), while it was not statistically significant for OS-HRs (p-value for interaction = 0.139).
Table 1. Main characteristics of the trials included. Ipi = Ipilimumab; Nivo = Nivolumab; Sun=Sunitinib; Ave=Avelumab; Axi = Axitinib; Atez = Atezolizumab; Beva = bevacizumab; Pembro = pembrolizumab; Sun = sunitinib.

| Ref. | Arms | Number of Patients | Median PFS In Months (Range) | PFS-HR | Median OS In Months (Range) | OS-HR | OR-R% | CR-R% |
|------|------|-------------------|-----------------------------|--------|-----------------------------|-------|-------|-------|
|      |      |       | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc |
| [15,16,24] | Ipi + Nivo | 425 | 60 | 8,2; (6,9–10) | 8,4; (5,2–24) | 0,77; (0,65–0,9) | 0,38; (0,61–0,97) | 35,6 | 31,2; (23-NE) | 0,66; (0,54–0,8) | 0,55; (0,33–0,9) | 42 | 56,7 | 11 | 18,3 |
| | Sun | 422 | 52 | 8,3; (7–8,8) | 4,9; (4–7) | - | - | 26,6; (22,1–33,4) | 13,6; (7,7–20,9) | - | - | 29 | 19,2 | 1 | 0 |
| [17,22] | Ave + Axi | 442 | 47 | 13,8; (11,1-NE) | 7; (5,3–13,8) | 0,69; (0,56–0,84) | 0,57; (0,325–1,003) | - | - | 0,78; (0,554–1,084) | - | 51,4 | 46,8 | 3,4 | 4,3 |
| | Sun | 444 | 61 | 8,4; (6,9–11,1) | 4; (2,7–5,7) | - | - | - | - | - | - | - | - | - | 25,7 | 21,3 | 1,8 | 0 |
| [18,23] | Pembro + Axi | 432 | 51 | 15,1; (12,6–17,7) | - | 0,69; (0,57–0,84) | 0,29; (0,54–1) | - | - | 0,53; (0,38–0,74) | 0,58; (0,21–1,59) | 59,3 | 58,8 | 5,8 | 11,8 |
| | Sun | 429 | 54 | 11,1; (8,7–12,5) | 8,4 | - | - | - | - | - | - | - | - | - | 35,7 | 31,5 | 1,9 | 0 |
| [19,21] | Atez + Beva | 454 | 68 | 11,2; (9,6–13,3) | 8,3; (5,4–12,9) | 0,83; (0,7–0,97) | 0,34; (0,52–0,79) | 33,6 | 18,3 | 0,93; (0,76–1,14) | 0,56; (0,32–0,96) | 37 | 49 | 5 | 10 |
| | Sun | 461 | 74 | 8,4; (7,5–9,7) | 5,3; (3,3–6,7) | - | - | 34,9; (27,8-NE) | 15; (8,7-NE) | - | - | 33 | 14 | 2 | 3 |
| [20] | Atez + Beva | 101 | 15 | 11,7; (8,4–17,3) | - | 0,82; (0,59–1,15) | 0,26; (0,63–1,54) | - | - | - | - | - | - | - | - |
| | Atezo | 103 | 16 | 6,1; (5,4–13,6) | - | 1,18; (0,86–1,63) | 0,44; (1–2,3) | - | - | - | - | - | - | - | - |
| | Sun | 101 | 14 | 8,4; (7–14) | - | - | - | - | - | - | - | - | - | - | - | - | - |
Figure 3. Interactions between HR for progression or death and sarcomatoid histology. Ipi = Ipilimumab; Nivo = Nivolumab; Sun = Sunitinib; Ave = Avelumab; Axi = Axitinib; Atez = Atezolizumab; Beva = Bevacizumab; Pemb = Pembrolizumab; Sun = Sunitinib.

Figure 4. Interactions between HR for death and sarcomatoid histology. Pooled estimates of $\Delta$CR-R between anti-PD-1/PDL-1 agents vs. sunitinib among the trials were 0.10, 95% [0.04; 0.16] in the sarcomatoid subgroup and 0.04, 95% [0.00; 0.07] in the non-sarcomatoid subgroup (Figure 5), while pooled estimates of $\Delta$PR-R were 0.21, 95% [0.16; 0.26] in the sarcomatoid subgroup and 0.18, 95% [0.05; 0.31] in the non-sarcomatoid subgroup (Figure 6).
The pooled differences in the sarcomatoid vs. non-sarcomatoid sub groups of ACR-R and ∆PR-R between anti PD-1/PDL-1 vs. sunitinib were 0.06 (95% CI: 0.02–0.10) and 0.03 (95% CI: 0.08–0.14), respectively. Pooled interaction was statistically significant for complete responses (p-value...
for interaction = 0.007), while it was statistically not significant for partial responses (\(p\)-value for interaction = 0.606).

Figure 7 shows the Leave-One-Out-analysis results for HR for death, HR for progression, complete response rate and partial response rate. Pooled interaction estimates were recalculated, with one study omitted each time, and ordered by effect size (low to high). For PFS-HR, pooled interaction estimates slightly changed, with the greatest change obtained by omitting the Avelumab +Axitinib vs Sunitinib study, although all the pooled interaction effects remained significant. As for the HR for death, although the pooled interaction estimates changed by omitting the Atezolizumab+Bevacizumab vs. Sunitinib phase III study, all the pooled interaction effects remained non-significant. As for complete response rate, all the pooled interaction effects remained significant, while as for partial response rate, the pooled interaction estimates changed drastically when omitting the study Ipilimumab+Nivolumab vs. Sunitinib study, but all the estimates remained non-significant.

The results of the network meta-analysis are presented in Table 2. In sRCC, ipilimumab + nivolumab had the highest rank for OS and RC-C, while avelumab + axitinib had the highest rank for PFS and atezolizumab + bevacizumab had the highest rank for PR-R.

Table 2. Results of the network meta-analysis. Anti PD-1/PDL-1 agents are ranked from best to worse according to the different efficacy end points considered.

| SARCOMATOID PFS-HR | Sarcomatoid ITT | Sarcomatoid OS-HR | ITT |
|---------------------|-----------------|-------------------|-----|
| Treatments P-Score  | Treatments P-Score | Treatments P-Score | Treatments P-Score |
| Ave+Ax     0,8678  | Ave+Ax  0,8463  | Ipi+nivo  0,6825  | Pembro+Ax  0,9551 |
| Atez+beva  0,6545  | Pembro+Ax  0,8463  | Atez+Beva  0,6624  | Ipi+nivo  0,708 |
| Pembro+Ax  0,6381  | Ipi+nivo  0,6265  | Pembro+Ax  0,5981  | Atez+Beva  0,2561 |
| Ipi+nivo  0,5404  | Atez+beva  0,4719  | Sun          0,057   | Sun          0,0808 |
| Atez       0,1854  | Sun          0,1695  |                 |               |
| Sun        0,1139  | Atez        0,0395  |                 |               |

| CR-R | PR-R |
|-------|------|
| SARCOMATOID | Non-sarcomatoid |
| Treatments P-Score | Treatments P-Score | Treatments P-Score | Treatments P-Score |
| Ipi+Nivo  0,946   | Ipi+Nivo  0,9989  | Atez+Beva  0,8438  | Atez+Beva  0,9989 |
| Pembro+Ax  0,7159  | Pembro+Ax  0,6024  | Ave+Ax  0,625     | Pembro+Ax  0,6662 |
| Atez+Beva  0,4785  | Atez+Beva  0,5292  | Ipi+Nivo  0,5621  | Ave+Ax  0,5849 |
| Ave+Ax     0,3288  | Ave+Ax  0,3209   | Pembro+Ax  0,4518  | Ipi+Nivo  0,1412 |
| Sun        0,0308  | Sun          0,0486  | Sun          0,0173  | Sun          0,1089 |
Figure 7. Leave-One-Out-Analyses. Pooled interaction estimates sorted by effect size.
5. Discussion

While sunitinib has been the standard of care in the first-line setting of advanced RCC for over a decade [25], with pazopanib representing a non-inferior treatment with a different toxicity profile [26], the therapeutic armamentarium in the first-line treatment setting has expanded to include several novel therapeutic options with evidence of improved efficacy vs. sunitinib, such as cabozantinib [27], axitinib + avelumab [17], axitinib + pembrolizumab [28], ipilimumab + nivolumab [15], atezolizumab + bevacizumab [19]. Indirect comparisons have been published to establish the optimal first-line treatment choice. One meta-analysis [5] including 16 trials (9,343 patients) that were evaluated for OS and 25 trials (11,771 patients) that were evaluated for PFS concluded that pembrolizumab plus axitinib (HR: 0.53; 95% CrI: 0.38–0.73), followed by nivolumab plus ipilimumab (HR: 0.63; 95% CrI: 0.50–0.79), had the highest chances of providing the maximum OS benefit vs. sunitinib, while cabozantinib (HR: 0.66; 95% CrI: 0.46–0.94) had the highest chances of providing the maximum PFS advantage vs. sunitinib. Concordant results are presented in the separately published meta-analysis by Hahn et al. [4].

As the number of therapeutic options grows, so does the importance of identifying readily available predictive factors to be potentially included in the therapeutic algorithm for optimal selection of the first-line treatment of RCC patients. While in the ‘targeted’ and ‘cytokine’ eras the therapeutic benefit appeared to be independent on the prognostic risk classification [3], the advent of a novel ‘immunotherapy era’ has shown that treatment efficacy can significantly vary across different risk classes, with ipilimumab + nivolumab being effective in the poor-/intermediate-risk class, but not in the good-risk class [16]. In the sub-group of patients at intermediate-/poor- prognosis, cabozantinib and pembrolizumab plus axitinib were also the most likely to provide the highest treatment benefit in terms of PFS and OS, respectively [5].

PD-L1 expression may also be a valuable predictive factor for anti PD-1/PDL-1 therapy, as shown in another recently published meta-analysis involving 4063 cases RCC patients randomized to anti PD-1/PDL-1 agent vs. sunitinib. OS improvement in unselected cases (HR = 0.65, 95% CI: 0.54–0.79; p < 0.001) was lower compared to PD-L1 positive cases (HR = 0.49, 95% CI: 0.36–0.67; p < 0.001), although the authors did not perform a formal statistical test to compare these differences. Similarly, pooled analysis of the unselected cases showed a statistically significant improvement in PFS with the use of anti PD1/PDL-1 agents (HR = 0.85; 95% CI: 0.72–0.99), which appeared to be greater in PDL-1 positive patients (HR = 0.65; 95% CI: 0.57–0.74). Response rates also appeared to improve in patients with positive PD-L1 expression (RR = 1.74; 95% CI: 1.21–2.49).

Importantly, sarcomatoid features at histology have been associated with PD-L1 expression, which could provide the biological background supporting our findings [29]. In fact, in a study sample of 26 sarcomatoid RCC specimens, PD-L1 expression was reported in 54% of cases, while among 29 specimens of clear cell RCC without sarcomatoid features, PD-L1 expression was reported only in 17% of cases [9]. Furthermore, sarcomatoid RCC may present a higher mutation burden compared to non sarcomatoid RCC [30], which is a known predictor of immunotherapy efficacy [31].

In our meta-analysis, we provided pooled estimates of outcomes in RCC patients with sarcomatoid features randomized to anti PD-1/PDL-1 agents vs. sunitinib and obtained a pooled PFS-HR of 0.57 and pooled OS-HR of 0.56. Compared to the ITT population, the ratios of pooled PFS-HRs was 0.64 (0.5–0.72), showing a 36% statistically significant improvement in HR-PFS of anti PD-1 agents vs. sunitinib in the sarcomatoid sub-group vs the ITT population. It is important to note that this result is an underestimation of the true ratio of PFS-HR in sarcomatoid patients vs. non sarcomatoid patients as the former are included in the ITT population, and no PFS data in non-sarcomatoid patients were available at the time of our systematic search. No statistically significant interaction was reported for OS-HR between sarcomatoid patients and the ITT population, which requires to be verified using the non-sarcomatoid sub-group rather the ITT population as a comparator for the sarcomatoid sub-group.

The absolute increase in CR rate with anti-PD-1 agent vs. sunitinib was 2.5 times higher in sarcomatoid vs. non-sarcomatoid subgroups (10% vs. 4%), with a statistically meaningful interaction. Achievement of a complete response has an established prognostic value in patients treated with
immunotherapy. In a retrospective study including a total of 23 patients treated with high dose interleukin 2 experiencing a complete response and 30 patients showing a partial response, all patients with partial responses, but only four with complete responses had experienced disease recurrence after (>10 years) follow-up. Furthermore, when we tried to rank anti PD-1/PDL-1 agents according to the different efficacy end points considered, ipilimumab + nivolumab ranked the highest in both CR-R and OS-HR.

Our meta-analysis has several types of limitations. First, sub-group data were mostly available in the abstract form and thus have not undergone rigorous peer-review, although grey literature has a recognized importance in systematic reviews [32]. Second, PFS and OS data were unavailable for non-sarcomatoid patients, so we could also estimate ratio between sarcomatoid patients and the entire ITT population. Third, the non-sarcomatoid sub-group also included patients with unknown sarcomatoid status. Fourth, sarcomatoid histology was not centrally reviewed in the trials assessed, nor was it uniformly defined, nor was a stratification factor. Nevertheless, we believe our meta-analysis has the merit to provide pooled estimates of measures of anti PD-1/PDL-1 efficacy in patients with a particularly aggressive histologic variant. As patients at intermediate/ poor prognosis, including those with sarcomatoid features, may also be candidates to cabozantinib, additional data are needed to establish caboza nibinib efficacy in patients with sarcomatoid tumors, which are known to express c-MET, one of the biological targets inhibited by cabozantinib [33].

In conclusion, presence of sarcomatoid features is a candidate predictive biomarker for efficacy of anti-PD-1/PDL-1 agents in RCC. Additional research represents a compelling need in order to establish the optimal anti PD-1/PDL-1-based regimen in patients with sarcomatoid RCC, as several combinations are available. Our results suggest that ipilimumab + nivolumab may represent a reference standard for RCTs in sarcomatoid RCC.

Author Contributions: Conception and design: C.B., G.D.L., N.L., C.I., S.D.P., V.R. (Valeria Romeo); acquisition of data: L.S., S.I., A.V., F.C., M.P., D.R., R.M., V.R. (Vittorio Riccio), F.C., P.D.P.; analysis and interpretation of data: PD., C.B., G.D.L.; drafting of the manuscript: C.B., G.D.L., N.L., C.I., S.D.P., P.D.; critical revision of the manuscript for important intellectual content: L.S., S.I., A.V., F.C., M.P., D.R., R.M., V.R. (Vittorio Riccio), C.C., P.D.P., V.R. (Valeria Romeo); Supervision: G.D.L. All authors have read and agree to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: C.B. wishes to thank Ermete Ottoni for his continued encouragement to carry out this work.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kidney Cancer Statistics. Available online: https://www.wcrf.org/dietandcancer/cancer-trends/kidney-cancer-statistics (accessed on 10 January 2020).
2. Capitanio, U.; Bensalah, K.; Bex, A.; Boorjian, S.A.; Bray, F.; Coleman, J.; Gore, J.L.; Sun, M.; Wood, C.; Russo, P. Epidemiology of Renal Cell Carcinoma. *Eur. Urol.* 2019, 75, 74–84. [CrossRef]
3. Buonerba, C.; Ferro, M.; Perri, F.; Calderoni, G.; Mambella, P.; Giordano, P.; Piscitelli, P.; Montanaro, V.; Aiesta, M.; Di Lorenzo, G. How can we improve prognostic models in renal cell carcinoma? *Expert Opin. Pharmacother.* 2015, 16, 1281–1283. [CrossRef]
4. Hahn, A.W.; Klaassen, Z.; Agarwal, N.; Haaland, B.; Esther, J.; Ye, X.Y.; Wang, X.; Pal, S.K.; Wallis, C.J. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *Eur. Urol. Oncol.* 2019, 2, 708–715. [CrossRef]
5. Wang, J.; Li, X.; Wu, X.; Wang, Z.; Zhang, C.; Cao, G.; Zhang, X.; Peng, F.; Yan, T. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. *EBioMedicine* 2019, 47, 78–88. [CrossRef]
6. Alevizakos, M.; Gaitanidis, A.; Nasioudis, D.; Msaouel, P.; Appleman, L.J. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. *Clin. Genitourin. Cancer* 2019, 17, e447–e453. [CrossRef] [PubMed]
7. El Mouallem, N.; Smith, S.C.; Paul, A.K. Sarcomatoid renal cell carcinoma: Biology and treatment advances. *Urol. Oncol. Semin. Orig. Investig.* 2018, 36, 265–271. [CrossRef] [PubMed]
8. Korenbaum, C.; Pierard, L.; Thiéry, A.; Story, F.; Lindner, V.; Lang, H.; Kurtz, J.-E.; Barthelemy, P. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. *Clin. Genitourin. Cancer* **2018**, *16*, e577–e586. [CrossRef]

9. Joseph, R.W.; Millis, S.Z.; Carballido, E.M.; Bryant, D.; Gatalica, Z.; Reddy, S.; Bryce, A.H.; Vogelzang, N.J.; Stanton, M.L.; Castle, E.P.; et al. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. *Cancer Immunol. Res.* **2015**, *3*, 1303–1307. [CrossRef] [PubMed]

10. Ged, Y.; Chen, Y.-B.; Knezevic, A.; Casuscelli, J.; Redzematovic, A.; DiNatale, R.G.; Carlo, M.I.; Lee, C.-H.; Feldman, D.R.; Patil, S.; et al. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. *Clin. Genitourin. Cancer* **2019**, *17*, e678–e688. [CrossRef] [PubMed]

11. Jadad, A.R.; Moore, R.; Carroll, D.; Jenkinson, C.; Reynolds, D.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control. Clin. Trials* **1996**, *17*, 1–12. [CrossRef]

12. Fisher, D.J.; Carpenter, J.R.; Morris, T.P.; Freeman, S.C.; Tierney, J.F. Meta-analytical methods to identify who benefits most from treatments: Daft, deluded, or deft approach? *BMJ* **2017**, *356*. [CrossRef] [PubMed]

13. Rücker, G.; Schwarzer, G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med. Res. Methodol.* **2015**, *15*, 58. [CrossRef] [PubMed]

14. Shim, S.R.; Kim, S.J.; Lee, J.; Rücker, G. Network meta-analysis: application and practice using R software. *Epidemiol. Health* **2019**, *41*, e2019013. [CrossRef] [PubMed]

15. Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Frontera, O.A.; Melichar, B.; Choueiri, T.K.; Plimack, E.R.; Barthélémy, P.; Porta, C.; George, S.; et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2018**, *378*, 1277–1290. [CrossRef]

16. Motzer, R.J.; I. Rini, B.; McDermott, D.F.; Frontera, O.A.; Hammers, H.J.; A Carducci, M.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol.* **2019**, *20*, 1370–1385. [CrossRef]

17. Motzer, R.J.; Penkov, K.; Haenen, J.; Rini, B.; Albiger, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1103–1115. [CrossRef]

18. Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanov, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Alekseev, B.; Soulières, D.; Melichar, B.; et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* **2018**, *380*, 1116–1127. [CrossRef]

19. Rini, B.I.; Powles, T.; Atkins, M.B.; Escudier, B.; McDermott, D.F.; Suarez, C.; Bracarda, S.; Stadler, W.M.; Donskov, F.; Lee, J.L.; et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. *Lancet* **2019**, *393*, 2404–2415. [CrossRef]

20. McDermott, D.F.; Huseni, M.A.; Atkins, M.B.; Motzer, R.J.; Rini, B.I.; Escudier, B.; Fong, L.; Joseph, R.W.; Pal, S.K.; Reeves, J.A.; et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat. Med.* **2018**, *24*, 749–757. [CrossRef]

21. Rini, B.I.; Motzer, R.J.; Powles, T.; McDermott, D.F.; Escudier, B.; Donskov, F.; Hawkins, R.E.; Bracarda, S.; Bedke, J.; Giorggi, U.D.; et al. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. *J. Clin. Oncol.* **2019**. [CrossRef]

22. Choueiri, T.K.; Larkin, J.M.G.; Pal, S.K.; Motzer, R.J.; Venugopal, B.; Alekseev, B.Y.; Miyake, H.; Gravis, G.; Bilen, M.A.; Chudnovsky, A.; et al. 910PD Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) versus sunitinib (S). *Ann. Oncol.* **2019**, *30*. [CrossRef]

23. Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanov, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Soulieres, D.; Melichar, B.; Vynnychenko, I.; et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. *J. Clin. Oncol.* **2019**, *37*. [CrossRef]
24. McDermott, D.F.; Choueiri, T.K.; Motzer, R.J.; Aren, O.R.; George, S.; Powles, T.; Donskov, F.; Harrison, M.R.; Cid, J.R.R.R.; Ishii, Y.; et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. *J. Clin. Oncol.* 2019, 37. [CrossRef]

25. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Négrier, S.; Szczylik, C.; Kim, S.T.; et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. *N. Engl. J. Med.* 2007, 356, 115–124. [CrossRef]

26. Motzer, R.J.; Hutson, T.E.; Cella, D.; Reeves, J.; Hawkins, R.; Guo, J.; Nathan, P.; Staehler, M.; De Souza, P.; Merchan, J.R.; et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. *N. Engl. J. Med.* 2013, 369, 722–731. [CrossRef]

27. Choueiri, T.K.; Halabi, S.; Sanford, B.L.; Hahn, O.; Michaelson, M.D.; Walsh, M.K.; Feldman, D.R.; Olencki, T.; Picus, J.; Small, E.J.; et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J. Clin. Oncol.* 2017, 35, 591–597. [CrossRef]

28. Chen, J.; Hu, G.; Chen, Z.; Wan, X.; Tan, C.; Zeng, X.; Cheng, Z. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. *Clin. Drug Investig.* 2019, 39, 931–938.

29. Kawakami, F.; Sircar, K.; Rodriguez-Canales, J.; Fellman, B.M.; Urbauer, D.L.; Tamboli, P.; Tannir, N.M.; Jonasch, E.; Wistuba, I.I.; Wood, C.G.; et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. *Cancer* 2017, 123, 4823–4831. [CrossRef]

30. Wang, Z.; Kim, T.B.; Peng, B.; Karam, J.A.; Creighton, C.J.; Joon, A.Y.; Kawakami, F.; Trevisan, P.; Jonasch, E.; Chow, C.-W.; et al. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. *Clin. Cancer Res.* 2017, 23, 6686–6696. [CrossRef]

31. Meléndez, B.; Van Campenhout, C.; Rorive, S.; Remmelink, M.; Salmon, I.; D’Haene, N. Methods of measurement for tumor mutational burden in tumor tissue. *Transl. Lung Cancer Res.* 2018, 7, 661–667. [CrossRef]

32. McAuley, L.; Pham, B.; Tugwell, P.; Moher, D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? *Lancet* 2000, 356, 1228–1231. [CrossRef]

33. Kammerer-Jacquet, S.-F.; Medane, S.; Bensalah, K.; Bernhard, J.-C.; Yaacoub, M.; Dupuis, F.; Ravaud, A.; Verhoest, G.; Mathieu, R.; Peyroneau, E.; et al. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. *Target. Oncol.* 2017, 12, 487–494. [CrossRef] [PubMed]